Additionally, our study reveals a significant upregulation of PLA2G16 expression in drug-resistant pancreatic cancer cells, with manipulation of PLA2G16 impacting cellular proliferation and sensitization to gemcitabine treatment, ultimately inhibiting cell growth and proliferation. The gene discussed is PLAAT3; the disease is familial pancreatic carcinoma.